Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical formulated methylene blue for inoperable or radiotherapy-unsuitable basal cell carcinoma
IRCT20191228045924N8Phase 2Completed
- Sponsor
- Mashhad University of Medical Sciences
- Start
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of methylene blue in basal cell carcinoma (BCC), sponsored by Mashhad University of Medical Sciences. Primary endpoint: Wound healing rate. Started Oct 2025; status: completed.
02
Drugs
methylene blue
03
Conditions
basal cell carcinoma (BCC)
Beyond the preview
Go deeper on IRCT20191228045924N8.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20191228045924N8.